15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 6 firms covering Lyell Immunopharma Inc, 6 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets range widely, $20.00 to $45.00 (about 2.3x), a sign of real disagreement on valuation. The average target of $37.17 sits 175% above the current $13.53. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 4 to 5 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.61 next quarter toward $-6.32 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 ratings
Strong Buy
Strong Buy00%
Buy6100%
Hold00%
Sell00%
Strong Sell00%
Based on 6 analysts giving stock ratings to Lyell Immunopharma Inc.
As of Sep, 5 of 5 firms rate LYEL a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
LYEL EPS & revenue forecast
EPS · NEXT QUARTER
$-1.61
Range $-1.61 – $-1.61 · 1 analysts
Next period, 1 analysts expect Lyell Immunopharma Inc to earn $-1.61 a share (range $-1.61 – $-1.61), versus — a year earlier. Full-year consensus is $-6.92, growing to $-6.32 the year after.
REVENUE · NEXT QUARTER
$2.4K
Range $0 – $10.0K · 1 analysts · -60% YoY
Revenue is expected to reach $2.4K (range $0 – $10.0K), -59.5% year-over-year. Full-year consensus is $11.9K, rising to $9.9K next year.
Top analysts covering Lyell Immunopharma Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on LYEL.
#1
Mitchell Kapoor
HC Wainwright & Co. · Rank #193
Buy
$45.00+232.6% to target
Overall win rate
34%
+ Follow
#2
Gil Blum
Needham · Rank #340
Buy
$44.00+225.2% to target
Overall win rate
26%
+ Follow
#3
SW
Stephen Willey
Stifel · Rank #345
Buy
$36.00+166.1% to target
Overall win rate
31%
+ Follow
#4
Reni J. Benjamin
JMP Securities · Rank #366
Buy
$34.00+151.3% to target
Overall win rate
32%
+ Follow
#5
YZ
Yuan Zhi
B. Riley Securities
Buy
$44.00+225.2% to target
Coverage
—
+ Follow
LYEL stock forecast FAQ
What is LYEL's average 12-month price target?+
The 6 analysts with a live target average $37.17 for Lyell Immunopharma Inc over the next 12 months, ranging from a $45.00 high to a $20.00 low.
Is LYEL stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 6 analyst ratings, 6 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for LYEL?+
The Street-high target is $45.00 (HC Wainwright & Co.), and the Street-low is $20.00 (LUCID CAPITAL MARKETS). The average of all 6 active targets is $37.17.
How many Wall Street analysts cover LYEL?+
6 analysts have an active rating on Lyell Immunopharma Inc, and 6 firms carry a live 12-month price target.
Who is the most accurate analyst covering LYEL?+
Among analysts who currently cover LYEL, Mitchell Kapoor of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #193). Their current call is Buy with a $45.00 target.
What is Lyell Immunopharma Inc's projected EPS for next quarter?+
The consensus estimate is $-1.61 per share (range $-1.61 – $-1.61) across 1 analysts. Full-year EPS is projected at $-6.92, rising to $-6.32 the following year.
How much revenue is Lyell Immunopharma Inc expected to report next quarter?+
Consensus revenue is $2.4K (range $0 – $10.0K). Full-year revenue is projected at $11.9K, growing to $9.9K next year.
Have analysts been upgrading or downgrading LYEL lately?+
As of Sep, 5 of 5 firms rate LYEL a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their LYEL calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
